A Nanofluidic Nanoplasmonic Platform for Multiplexing Detection of Cancer Biomark

描述（由申请人提供）：该项目旨在开发一种新型纳米流体-纳米等离子体平台，以实现生物结合过程的多重监测，特别是用于检测生物流体中的癌症生物标志物。与目前的大尺寸，笨重的表面等离子体共振（SPR）传感技术相比，所提出的设备是由一个多层纳米结构阵列，结合了纳米流体的功能，有效的试剂运输和纳米等离子体传感，同时。该阵列以这样的方式设计，以允许显着增强的非常光学透射率（EOT），主峰在NIR范围内（700- 1200 nm），透射率和光谱由嵌入的金属膜中操纵的表面等离子体（SP）确定。阵列结构容易与微流体通道接口，使其适合于在芯片实验室设备中进行高度并行的通量筛选。新平台提供更大的吞吐量兼容性，与当前光栅SPR传感器相比，折射率变化的灵敏度提高了5- 10倍，分析物传输的效率提高了，EOT强度与NIR范围光谱显著增加，有利于信噪比检测，成本降低，周转时间快-有利于生物标志物的早期检测和医疗保健和生物医学研究中的其他应用。第一阶段研究旨在开发（设计，制造和测试）集成在微流体通道中的纳米流体等离子体阵列的原型，以适应纳米限制流通运输验证的协议，并以明确证明生物标志物的改进等离子体传感而告终。纳米结构阵列和设备优化以及与用于检测真实的生物流体中的多种生物标志物的样品处理微流体的集成计划用于第二阶段。在SPR传感器和BioMEMS/纳米流体（CFDRC），纳米等离子体和纳米光子学（匹兹堡大学）和疾病蛋白质组学（诊断/预后生物标志物）（加州大学洛杉矶分校）的专业知识的多学科合作伙伴关系已经形成。 公共卫生相关性：存在对便携式、无标记、高通量分析工具的明确需求，所述分析工具不仅在医学应用（临床或自我诊断）中而且在生物医学研究（蛋白质组学、药物设计和评价）中适合于早期检测痕量水平的生物流体中的癌症生物标志物和相关生物物种。该项目的总体目标是开发一种基于纳米流体等离子体的传感平台，该平台可以很容易地与微流体设备集成，并实现并行传输SPR传感技术和芯片实验室技术（样品分离，混合，稀释等），用于开发下一代基于纳米等离子体的生物分析工具，该工具能够多重区分生物标志物以及高并行通量研究。

DESCRIPTION (provided by applicant): This project aims to develop a novel nanofluidic-nanoplasmonic platform to realize multiplexed monitoring of biological binding processes, specifically for detection of cancer biomarkers in bio-fluids. In contrast to current large-sized, cumbersome surface plasmon resonance (SPR) sensing technology, the proposed device is comprised of a multilayer nanostructured array that combines the functions of nanofluidics for effective reagent transport and nanoplasmonics for sensing, concurrently. The array is designed in such a way as to permit significantly enhanced Extraordinary Optical Transmission (EOT) with a primary peak in the NIR range (700- 1200 nm), with the transmission and spectra being determined by the surface plasmons (SP) manipulated in the embedded metal film. The array structure readily interfaces with microfluidic channels, making it amenable to highly parallel throughput screening in a lab-on-chip device. The new platform offers greater throughput compatibility, 5-10X enhanced sensitivity of refractive index changes compared to current grating SPR sensor, improved efficacy of analyte transport, significantly increased EOT intensity with NIR range spectra for favorable signal-to-noise detection, lower cost, and rapid turnaround times - benefiting early detection of biomarkers and other applications in healthcare and biomedical research. The Phase I study seeks to develop (design, fabricate, and test) a prototype of the nano-fluidic-plasmonics array integrated in a microfluidic channel, to adapt protocols for nano-confined flow-through transport validation and to culminate with a clear demonstration of improved plasmonic sensing of biomarkers. The nanostructure arrays and device optimization as well as integration with sample handling microfluidics for detecting multiple biomarkers in real biofluids are planned for Phase II. A multi-disciplinary partnership with expertise in SPR sensors and BioMEMS/nanofluidics (CFDRC), nanoplasmonics and nanophotonics (University of Pittsburgh), and disease proteomics (diagnostic/prognostic biomarkers) (UCLA) has been formed. PUBLIC HEALTH RELEVANCE: A clear need exists for portable, label-free, high throughput analytical tools that are suited for early detection of cancer biomarkers and related biological species in bio-fluids at trace amount levels, not only in medical applications (clinical or self-diagnosis) but also in biomedical research (proteomics, drug design and evaluation). The overall objective of this project is to develop a nano-fluidic-plasmonics-based sensing platform which can be readily integrated with microfluidics devices, and enable in-parallel transmission SPR sensing technology and lab-on-chip technology (sample separation, mixing, dilution, etc) for developing next generation nanoplasmonics-based bioanalytical tools that are capable of multiplexing differentiation of biomarkers as well as high parallel throughput studies.